Package 61958-1901-1

{"route": ["ORAL"], "spl_id": "7bb9d232-d878-47d0-8262-abc4d06b37f7", "openfda": {"nui": ["N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423", "N0000000127", "N0000175887", "N0000185507", "N0000175462", "M0015066", "N0000009947"], "unii": ["LW2E03M5PG", "4GDQ854U53", "G70B4ETF4S", "FWF6Q91TZO"], "rxcui": ["1721613", "1721619"], "spl_set_id": ["34784acf-15ed-4715-b504-eb30430518e9"], "pharm_class_cs": ["Nucleosides [CS]"], "pharm_class_epc": ["Cytochrome P450 3A Inhibitor [EPC]", "Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]", "HIV Integrase Inhibitors [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Gilead Sciences, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET in 1 BOTTLE, PLASTIC (61958-1901-1)", "package_ndc": "61958-1901-1", "marketing_start_date": "20151105"}], "brand_name": "Genvoya", "product_id": "61958-1901_7bb9d232-d878-47d0-8262-abc4d06b37f7", "dosage_form": "TABLET", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitor [EPC]", "Cytochrome P450 3A Inhibitors [MoA]", "HIV Integrase Inhibitors [MoA]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleosides [CS]", "Nucleosides [CS]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "61958-1901", "generic_name": "elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide", "labeler_name": "Gilead Sciences, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Genvoya", "active_ingredients": [{"name": "COBICISTAT", "strength": "150 mg/1"}, {"name": "ELVITEGRAVIR", "strength": "150 mg/1"}, {"name": "EMTRICITABINE", "strength": "200 mg/1"}, {"name": "TENOFOVIR ALAFENAMIDE FUMARATE", "strength": "10 mg/1"}], "application_number": "NDA207561", "marketing_category": "NDA", "marketing_start_date": "20151105", "listing_expiration_date": "20261231"}